Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Molecular Partners AG's Enterprise Value is CHF-62.15 Mil.
Molecular Partners AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was CHF-58.50 Mil. Therefore, Molecular Partners AG's EV-to-EBIT ratio for today is 1.06.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Molecular Partners AG's Enterprise Value is CHF-62.15 Mil.
Molecular Partners AG's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was CHF-56.08 Mil. Therefore, Molecular Partners AG's EV-to-EBITDA ratio for today is 1.11.
Molecular Partners AG Enterprise Value Historical Data
The historical data trend for Molecular Partners AG's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Molecular Partners AG's Enterprise Value
For the Biotechnology subindustry, Molecular Partners AG's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's Enterprise Value falls into.
Molecular Partners AG Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Molecular Partners AG's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG (CHIX:MOLNz) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Molecular Partners AG's current Enterprise Value is CHF-62.15 Mil.
Molecular Partners AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-58.50 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Molecular Partners AG's EV-to-EBITDA for today is:
Molecular Partners AG's current Enterprise Value is CHF-62.15 Mil.
Molecular Partners AG's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-56.08 Mil.
Molecular Partners AG's current Enterprise Value is CHF-62.15 Mil.
Molecular Partners AG's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF6.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG Enterprise Value Related Terms
Thank you for viewing the detailed overview of Molecular Partners AG's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Molecular Partners AG (CHIX:MOLNZ) Business Description
Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHIX:MOLNZ has been successfully added to your 